We are advising Endo on the transaction

Davis Polk is advising Endo, Inc. on the divestiture of its International Pharmaceuticals business primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc. The closing of the transaction is subject to the satisfaction of customary regulatory conditions including anti-trust clearance in Canada and is expected to occur in mid-2025.

Headquartered in Malvern, Pennsylvania, Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies.

Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and commercializing innovative prescription pharmaceuticals, primarily serving Canada and Latin America.

The Davis Polk corporate team includes partner Michael Davis and associates Katherine Anne Cody, Alexander J. Yang, Jeff (Zefang) Wu and Yi Bao. Partner David R. Bauer and counsel Samantha Lefland are providing intellectual property advice. Partner Veronica M. Wissel and associate Laetitia Krisel are providing executive compensation advice. Partner Michael Mollerus is providing tax advice. All members of the Davis Polk team are based in the New York office. 

Copy link to share post